Form 4: Amicus Therapeutics Officer Sells Shares for Tax

Amicus Therapeutics' Chief Accounting Officer, Samantha Prout, reported the sale of common stock totaling 15,683 shares for tax purposes.

Summary

• Samantha Prout, Chief Accounting Officer of Amicus Therapeutics, Inc. (FOLD), reported transactions involving the disposition of common stock.
• On January 2, 2026, 3,443 shares of common stock were disposed of at a price of $14.27 per share.
• On January 3, 2026, an additional 12,240 shares of common stock were disposed of at a price of $14.27 per share.
• These transactions, identified by transaction code 'F', represent shares withheld to cover tax obligations related to equity awards.
• The transactions were made pursuant to a Rule 10b5-1(c) plan.
• Following these dispositions, Samantha Prout directly beneficially owns 125,951 shares of Amicus Therapeutics common stock.

Sentiment

Score: 5

Explanation: The filing reports a routine insider transaction for tax withholding purposes, which is a neutral event and does not reflect positively or negatively on the company's performance or outlook.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This is a routine insider transaction report (Form 4) for tax withholding purposes, which is common practice for executives receiving equity compensation. It does not provide specific insights into broader industry trends or competitive positioning.

Stakeholder Impact

• Shareholders: The reduction in direct holdings by a key officer is a routine event for tax purposes and is generally not indicative of a change in management's confidence in the company. The overall impact on shareholder sentiment is expected to be minimal.

Key Dates

Keywords

Amicus Therapeutics, FOLD, Samantha Prout, Insider Transaction, Form 4, Common Stock, Tax Withholding, Beneficial Ownership, Chief Accounting Officer